innovative med concepts is an international trade and development company located in 1837 commons north drive, tuscaloosa, al, united states.
Company profile
Ticker
VIRI
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Virios Therapeutics, LLC
SEC CIK
Corporate docs
IRS number
454618270
VIRI stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
6 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
DEFA14A
Additional proxy soliciting materials
27 Feb 24
8-K
Departure of Directors or Certain Officers
27 Feb 24
DEF 14A
Definitive proxy
2 Feb 24
PRE 14A
Preliminary proxy
22 Jan 24
8-K
Regulation FD Disclosure
3 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
Transcripts
VIRI
Earnings call transcript
2023 Q3
13 Nov 23
VIRI
Earnings call transcript
2023 Q2
10 Aug 23
VIRI
Earnings call transcript
2022 Q3
14 Nov 22
VIRI
Earnings call transcript
2022 Q2
13 Aug 22
VIRI
Earnings call transcript
2022 Q1
13 May 22
VIRI
Earnings call transcript
2021 Q4
17 Mar 22
VIRI
Earnings call transcript
2021 Q3
11 Nov 21
VIRI
Earnings call transcript
2021 Q2
13 Aug 21
VIRI
Earnings call transcript
2021 Q1
13 May 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.79 mm | 4.79 mm | 4.79 mm | 4.79 mm | 4.79 mm | 4.79 mm |
Cash burn (monthly) | (no burn) | 416.86 k | 424.76 k | 533.21 k | 320.15 k | 506.06 k |
Cash used (since last report) | n/a | 2.78 mm | 2.84 mm | 3.56 mm | 2.14 mm | 3.38 mm |
Cash remaining | n/a | 2.00 mm | 1.95 mm | 1.23 mm | 2.65 mm | 1.41 mm |
Runway (months of cash) | n/a | 4.8 | 4.6 | 2.3 | 8.3 | 2.8 |
Institutional ownership, Q2 2023
14.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 8 |
Closed positions | 9 |
Increased positions | 7 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 945.27 mm |
Total shares | 2.80 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Brian David Corday | 1.33 mm | $0.00 |
IOI Ionic Ventures | 697.29 k | $0.00 |
Vanguard | 211.00 k | $291.18 mm |
Geode Capital Management | 147.27 k | $203.23 mm |
STT State Street | 52.83 k | $72.90 mm |
Susquehanna International | 52.64 k | $72.64 mm |
Renaissance Technologies | 46.40 k | $64.00 k |
Citadel Advisors | 33.30 k | $45.95 mm |
McCollum Christoferson | 30.70 k | $42.37 mm |
Raymond James & Associates | 30.00 k | $41.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 24 | Gregory Scott Duncan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.357 | 138,835 | 49.56 k | 138,835 |
26 Feb 24 | Ralph Grosswald | Stock Option Common Stock | Grant | Acquire A | No | No | 0.357 | 62,568 | 22.34 k | 62,568 |
26 Feb 24 | Roger Michael Gendreau | Stock Option Common Stock | Grant | Acquire A | No | No | 0.357 | 88,085 | 31.45 k | 88,085 |
26 Feb 24 | Angela Walsh | Stock Option Common Stock | Grant | Acquire A | No | No | 0.357 | 63,618 | 22.71 k | 63,618 |
26 Feb 24 | Richard Alan Burch | Stock Option Common Stock | Grant | Acquire A | No | No | 0.357 | 2,917 | 1.04 k | 2,917 |
News
Virios Therapeutics Announces Publication Of International Patent For IMC-2 Covering Antiviral Treatment Of Long-COVID
26 Mar 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
25 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
22 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Virios Therapeutics Q4 2023 GAAP EPS $(0.06) Beats $(0.09) Estimate
29 Feb 24
Press releases
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
26 Mar 24
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
28 Feb 24